All posts by imreal

Lessons Learned from Clinical Trial Inspections, Upcoming Webinar Hosted by Xtalks


It’s now more important than ever to ensure the trials eClinical systems are on the right path, run smoothly and reach the right patients at the right time.

Clinical trials continue to grow in cost, involvement, scope and complexity. Couple that with turnover and increased scrutiny from clinical trial inspections and one thing is certain: they need some continued maintenance. It’s now more important than ever to ensure the trials eClinical systems are on the right path, run smoothly and reach the right patients at the right time.

This webinar will take attendees through the what, why and how of putting together a care plan for a clinical trial. The featured speaker will discuss some great methodologies and some that are best left on the side of the road.

Join Matthew Lowrie, QA Manager, ASQ CQA, Almac, for the live webinar on Wednesday, November 2, 2022, at 1pm EDT (10am PDT).

For more information, or to register for this event, visit Care is Critical: Lessons Learned from Clinical Trial Inspections.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:

Vera Kovacevic

Tel: +1 (416) 977-6555 x371

Email: vkovacevic@xtalks.com

Share article on social media or email:

Comagine Health Awarded Contract to Study Long COVID


“As we enter a new phase of the pandemic, it’s critical that we understand the long-term impact of COVID-19 to help inform future decisions about the health care system, policy and program development,” said Marc Bennett, Comagine Health’s president and chief executive officer.

Comagine Health was recently awarded a five-year contract with the Centers for Disease Control and Prevention to track the burden, distribution, and impact of post-COVID-19 conditions. The work focuses on diverse populations of children, adolescents, and adults in Utah, New York City, and the Bronx. Comagine Health will partner with Boise State University, BeyondHIE, BronxRHIO, the Utah Health Information Network (UHIN), and FindHelp.

Comagine Health has a deep history of managing scientific studies and performing advanced analytics using various health data sources. In this project, the data solutions team will use clinical data from two health information exchanges (HIEs), augmented with social determinants of health data, to identify, track and analyze the long-term impact of COVID-19 on patients after their diagnoses.

As a part of this collaborative effort, the principal investigator and co-investigators from Boise State University will contribute their expertise in surveillance and developing and running cohort studies. BeyondHIE will coordinate with BronxRHIO and UHIN around HIE data collection and aggregation.

“The coronavirus has placed a disproportionate burden on certain populations, including people of color, the elderly, and those with pre-existing conditions,” said Marc Bennett, Comagine Health’s president and chief executive officer. “As we enter a new phase of the pandemic, it’s critical that we understand the long-term impact of COVID-19 to help inform future decisions about the health care system, policy, and program development.”

Sara Hallvik, Comagine Health’s vice president of data solutions, added, “The pandemic has illuminated a need for us to understand how the virus will impact different populations not only for the coming months, but for the coming years. Our team is ready to deploy advanced analytic methods to answer these important questions, as well as to build capacity to use surveillance information to guide COVID-19 prevention and care efforts.”

Share article on social media or email:

AristaMD’s Virtual Healthcare Technology Conference to Include Speakers from Stanford Health Care


News Image

AristaMD, a digital healthcare company specializing in care transition solutions, is pleased to announce that leaders from Stanford Health Care are the latest to join its roster of speakers slated for its upcoming conference, Healthcare Technology: Optimizing Care Delivery and Transition, taking place on Friday, Oct. 28 at 11 a.m. – 3:30 p.m. EDT. The event is free to attend for those in the healthcare space and will be taking place virtually online.

Conference attendees may expect to hear from a number of other healthcare experts, including those from Stanford Health Care, all sharing their first-hand accounts of the transformative impact technology has on the quality of care for health plans, hospital systems, clinics, primary and specialty care practices, home health care companies, and so much more.

“We are pleased to be joining AristaMD’s conference alongside other leaders in the healthcare space to educate organizations and specialists on the success eConsults have on extending the reach of specialty care in the community in a respectful, collaborative, and additive way,” said Tip Kim, Chief Market Development Officer at Stanford Health Care. “To overcome the issues plaguing care coordination between primary care physicians and specialists, primary care physicians must embrace tools and resources like eConsults that extend their clinical domain, reducing the overall cost of care.”

The late-October conference will be hosted by Crystal Mullis, Vice President of Member-Backed Ventures, Vizient, the nation’s largest member-driven healthcare performance improvement company. The complete lineup of sessions and medical experts who will be presenting on each topic includes:

  • eConsults – Extending the reach of specialty care in the community in a respectful, collaborative and additive way by Tip Kim, Chief Market Development Officer at Stanford Health Care and Lena Giang, Digital Health Senior Manager at Stanford Health Care
  • Referral strategies to improve behavioral health access and care by John A. Javis, Chief Executive Officer at Behavioral Health New York City (BHNYC) IPA; Tracy Schneider, Clinical Director at Behavioral Health New York City (BHNYC) IPA and Dana Calderone, Administrative Assistant at Behavioral Health New York City (BHNYC) IPA
  • AFib – tips and tricks for the PCP by Jana Goldberg, MD, FACC, who serves as National Medical Director, Vice President of Clinical at Heartbeat Health
  • Health Equity: Expanding our understanding of care access and delivery to improve outcomes in vulnerable populations by Shelley Davis MSN, RNC, CCM, who serves as Vice President of Clinical Strategy at Lightbeam Health Solutions
  • Managing through difficult times, incorporating new data and tools to make your job easier by Pam Gould, Chief Growth Officer at AristaMD and Jon Gautsch, Sr. Vice President of Engineering at AristaMD


“We’re excited to provide a range of educational topics at this year’s conference, including clinical care, innovations in managing patient access, solutions for staffing shortages, and increased patient demand,” said Brooke LeVasseur, CEO of AristaMD. “We aim to provide expert sessions relatable to various organizations and roles that will have long-lasting impacts on care delivery and transition, ensuring equal opportunity to patient care for years to come.”

With a mission to use technology to expedite time to treatment, decrease costs and drive better patient outcomes, AristaMD’s team is intimately familiar with the benefits and challenges of healthcare access. AristaMD’s platform enables healthcare organizations to coordinate and collaborate to improve access to care. AristaMD’s eConsult solution significantly impacts the care plan in greater than 90 percent of patient cases. More than 70 percent of routine clinical referrals can be safely and effectively addressed by eConsults, expanding the scope of care and allowing patients to receive timely, effective treatment. The platform also streamlines the referral process for clinics, specialists, and their patients. Automating the referral process allows administrative staff to spend less time on the phone and eliminates most manual processes.

Anyone interested in attending the virtual healthcare technology conference may register online at http://www.aristamd.com/healthcare-technology. For more information on AristaMD, visit http://www.aristamd.com.

About AristaMD AristaMD’s care transition solutions, including eConsults and referral management tools, empower providers to conduct electronic physician-to-physician consultations, facilitate the selection and scheduling of in-person specialist visits, trigger automatic follow-up activities critical to patient care, and schedule peer-to-peer reviews for insurance authorization. Electronic referral management and eConsults significantly improve the patient referral process and deliver greater access to timely, equitable, high-quality care. For additional information, visit http://www.aristamd.com, or follow AristaMD on LinkedIn and Twitter.

# # #

Share article on social media or email:



CoverRight Collaborates with Mark Cuban Cost Plus Drug Company to Help Medicare Beneficiaries Lower Drug Costs


News Image

This relationship comes at the perfect time as Medicare AEP just started so consumers can evaluate their 2023 drug coverage and find the best solution that lowers their costs.

CoverRight, the leading digital health platform revolutionizing the Medicare plan selection process, today announced its collaboration with Mark Cuban Cost Plus Drug Company. CoverRight is the first digital Medicare selection platform to integrate with Cost Plus Drugs, demonstrating its continued commitment to helping consumers get the most out of their healthcare, including lowering the cost of prescription medications.

This timing comes at the beginning of the Medicare Annual Enrollment Period (‘AEP’) which started on October 15.

“Prescription drug costs can be a large component of total annual out-of-pocket expenses for a Medicare beneficiary. Medication prices can vary widely by plan, geography, and even within the same zip code. With continued healthcare cost inflation in the U.S., it’s becoming ever more important to help consumers save” explained Richard Chan, CoverRight’s Founder & CEO. “This relationship comes at the perfect time as AEP just started so consumers can evaluate their 2023 drug coverage and find the best solution that lowers their costs.” Chan continued.

CoverRight has made its Medicare drug comparison tool available to its customers. With a few pieces of information, consumers can easily check to find the best Medicare drug plan for them through CoverRight’s platform. The technology platform will also show consumers alternate ways they can save on their medication. As part of this new integration with Mark Cuban Cost Plus Drug Company, the cost of available medications available at Cost Plus Drugs will be listed directly on CoverRight’s platform making it easy for consumers to compare the cost of a prescription between a Medicare plan and directly from Cost Plus Drugs.

“This can mean that someone might be able to find a less expensive way to fill their prescriptions and/or enroll in a less expensive drug plan. Our customers can simply order their medication through Cost Plus Drugs if they find that they can save” explained Chan. “Drug program adherence is a critical component of maintaining health and we want our customers to access all available options to help them achieve this” he added. CoverRight’s dedicated team of Medicare experts are also available to help customers through the analysis.

Alex Oshmyansky, Md, PhD. – CEO of Cost Plus Drugs added “we are excited to work with CoverRight to bring lower prescription drug prices to consumers who are on Medicare. Cost Plus Drugs and CoverRight share a common mission of providing consumers the lowest possible price for their prescription medication so they can maximize their health options in retirement. With the CoverRight integration, Medicare beneficiaries can access additional transparency not previously available and be confident they are getting a fair price for their medications.”

About CoverRight

CoverRight.com is a digital-first health platform focused on retirees. The company aims is to make Medicare more transparent and accessible for America’s 60 million Medicare beneficiaries. CoverRight simplifies a traditionally confusing and complex decision by combining technology with a digital concierge experience to deliver consumers a simple, delightful, and comprehensive Medicare plan selection and enrollment experience. The company’s vision is to become the go-to retirement concierge platform to help retirees manage and navigate health and finance in retirement.

About Mark Cuban Cost Plus Drug Company

The Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries nearly 1,000 prescription products, delivered by mail to thousands of happy customers every day. Cost Plus Drugs is working with health plans, managed-care organizations, pharmacy benefits managers (PBMs) and self-insured employers to bring these same savings to employer-sponsored benefit plans nationwide.

Share article on social media or email:

CSI Partners with Financial Giant J.P. Morgan to Fuel U.S. Market Growth


Terry Mirza, President, CSI

Terry Mirza, President, CSI

We wanted a strong + committed financial backer with a rich history in the American economic fabric to fuel our future. We wanted a trusted partner that shared common values + a desire to redefine the customer experience so our culture could align as we grow together.Terry MirzaPresident, CSI

Compugen Systems Inc (CSI)., is proud to announce that after careful consideration, the company has selected financial institution, J.P. Morgan, to fuel its continued growth across the U.S. market. J.P. Morgan is viewed as a progressive leader and was chosen, in part, for its use of data and technology to drive an improved customer experience—a philosophy equally shared by CSI.

CSI has been growing its U.S. presence steadily and strategically since opening its first office in 2015, doubling in revenue year-over-year (YoY). The company currently serves over 100 companies and counting throughout 35 states and 176 cities with key industries of focus including energy, retail, manufacturing, and mid-market healthcare. CSI is on track to continue this trajectory as the company projects to double in revenue once again by year-end.

As a privately held company, CSI’s latitude to live its mission, vision, and values without added shareholder pressure is considered a strong differentiator by its senior leadership team. The partnership with J.P. Morgan is a testament to its confidence in CSI amid today’s rapidly changing economic conditions, which include rising interest rates and inflation.

President Terry Mirza credits J.P. Morgan’s “bullish view on the market” as a leading advantage that will help CSI to reach its full potential. He notes that the firm’s vast portfolio offers the financial underpinning CSI was looking for as it continues to invest, grow, and expand into 2023.

About Compugen Systems Inc.

Compugen Systems, Inc. (CSI,) an affiliate of Compugen Inc., is an IT service delivery company that focuses on enabling your business outcomes. By coupling innovative technology-based services in the Modern Workspace and Hybrid IT with our uniquely crafted managed, professional, and field services; we’re redefining the customer experience. We believe that every day we have, is another opportunity to innovate, inspire, and impact our world for the better. Join us at http://www.compugen.us. 

Share article on social media or email:

Michael Todd joins Healthy Food Ingredients as Chief Executive Officer


Michael Todd, Healthy Food Ingredients CEO

As CEO, Todd will lead HFI’s focus on sustainably sourced on-trend ingredients, bringing innovation to customers.

Healthy Food Ingredients (HFI) is pleased to announce Michael Todd has joined the company as Chief Executive Officer.

As CEO, Todd will lead HFI’s focus on sustainably sourced on-trend ingredients, bringing innovation to customers.

Todd brings extensive industry experience from previously held executive positions at SunOpta, ADM, and most recently as CEO of Nutriati. His visionary leadership will advance HFI’s mission, with a focus on sustainability and regenerative agriculture while providing functional, value-added solutions.

“I am honored to join the Healthy Food Ingredients team and to drive the next stage of evolution at HFI. The company has built an incredibly strong core business and we will leverage the platform for growth,” commented Todd.

Brad Hennrich, HFI’s former President and CEO, continues to play an active role within the company as an advisor to the CEO and senior management and member on HFI’s board of directors. In addition, Hennrich will cultivate long-term customer and supplier partnerships. “With HFI’s strong financial performance and outlook, we are excited to have Michael’s leadership and expertise,” noted Hennrich.

“We are thrilled to welcome Michael with his established background in specialty ingredients, clear sense of mission and shared core values,” said Jim Shorin, co-chairman of HFI’s Board of Directors. “He will lead HFI in a robust growth trajectory and continue HFI’s resolute commitment to the ingredients industry.”

About Healthy Food Ingredients (HFI)

As an ingredient solutions provider, HFI is meeting demand for sustainable, on-trend ingredients from transparency to innovation.

Starting with a sustainable supply chain, backed by IntegriPure®, its innovative micro reduction process, HFI offers a full portfolio of ingredients including non-GMO, organic and gluten-free pulses, grains, seeds, flax, expeller oils, and signature product Suntava Purple Corn™, with unique processing capabilities for milling, flaking and blending and consumer-ready products.

HFI is dedicated to delivering safe, healthy, premium-quality ingredients in partnership with its diverse grower network.

Learn more at HFIfamily.com.

HFI is supported by Horizon Holdings, LLC, a San Francisco-based private investment firm with a significant track record in successfully building private and public companies.

Share article on social media or email:

Surgical experts publish updated guidance for treating rare but potentially serious jawbone condition


News Image

“Our goal in issuing this update is to educate both our peers in medicine and patients about the evolving knowledge base in addressing MRONJ,” said Thomas B. Dodson, DMD, MPH, article co-author and editor-in-chief of the Journal of Oral and Maxillofacial Surgery, AAOMS’s official journal

The American Association of Oral and Maxillofacial Surgeons (AAOMS) has issued updated guidance for treating a rare but potentially serious jawbone condition that can impact patients taking antiresorptive medications to treat certain cancer types.

Medication-related osteonecrosis of the jaw, or MRONJ, is often-painful and characterized by exposed dying bone in the upper and lower jaws, swelling of the gums and loosening of previously stable teeth.

To help patients and healthcare providers navigate this clinical concern, oral and maxillofacial surgery experts analyzed literature and revised guidance to reflect current best practices. The 2022 recommendations – published in the Journal of Oral and Maxillofacial Surgery – prioritize preventing the disease while continuing cancer treatment necessary to maintain quality of life and support bone health.

“Although no individual nor collection of strategies eliminates all MRONJ risk, certain preventive procedures can make a difference,” said lead author Salvatore L. Ruggiero, DMD, MD, a practicing surgeon and professor at the Stony Brook School of Dental Medicine in New York. “Maximizing overall patient well-being is always the preference.”

Among strategies for reducing the risk of MRONJ: maintaining good oral hygiene, performing high-risk surgical procedures prior to initiating drug therapies, quitting smoking and optimizing diabetes care.

Authors agree that prevention starts with realizing that patients receiving bone-preserving medications (antiresorptives) face altered wound-healing capacity, another potential risk factor for developing MRONJ. Healthcare providers must recognize the importance of coordinating dental care and treatment planning for osteoporosis and cancers involving these therapies, they wrote.

Doing so requires continuous efforts to educate patients, dentists and medical professionals about the real risks associated with antiresorptives and the clinical paradigm shift needed to mitigate MRONJ, researchers wrote.

AAOMS emphasizes the importance of a multidisciplinary approach to treating patients receiving such treatment. This also may apply to other substances used to stimulate the immune system or targeted therapies taken alone or in combination with antiresorptives (brand names such as Fosamax, Boniva and Prolia). Team-based MRONJ care includes consulting an appropriate dental professional when a doctor determines a patient could benefit from these medications.

“Oral and maxillofacial surgeons are versed in treating this clinical concern, and it is crucial that oncologists, rheumatologists and other providers work with our specialty to prevent and treat it,” said Thomas B. Dodson, DMD, MPH, article co-author and editor-in-chief of the Journal of Oral and Maxillofacial Surgery, AAOMS’s official journal. “Our goal in issuing this update is to educate both our peers in medicine and patients about the evolving knowledge base in addressing MRONJ.”

It is important to understand that patients at risk for or with MRONJ also may present with other issues that appear similar, authors wrote. Commonly misdiagnosed conditions may include dry socket, sinusitis, gingivitis and periodontitis. Therefore, they said it is important for patients to undergo a detailed clinical and radiographic examination by an experienced oral healthcare practitioner to diagnose MRONJ.

There are several other local, potentially predisposing factors – including tooth extraction and operations on the thickened ridge of the bone that contains tooth sockets. Other concerns such as steroid and tobacco use may increase risk. The danger of developing MRONJ is higher in patients who have received antiresorptive medications for metastatic bone disease (less than 5 percent) compared to those receiving such drugs for osteoporosis (less than 0.05 percent).

Surgical management of MRONJ is increasingly considered a viable method of treatment for all stages of the disease, according to the 2022 guidance. These procedures involve the removal of necrotic jawbone until viable bone is encountered. AAOMS has developed a series of algorithms to assist doctors in streamlining and determining the correct care pathway for individual patients. A departure from the three previous position papers, the 2022 recommendations recognize the value of surgical intervention regardless of MRONJ disease stage.

AAOMS supports continued oncologic treatment for MRONJ patients whether they are receiving antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications. Authors wrote that quality of life is typically managed by preventing new areas of necrosis, controlling secondary infections, offering pain control and educating patients.

Additionally, the new guidance deemphasizes the role of medications other than antiresorptives in causing the condition. Studies suggest the cause is likely multifactorial, stemming both from drugs prescribed alongside inflammation or infection. A research review failed to prove if a drug holiday (ceasing use of medications for a defined period) is beneficial or harmful to patients, the authors wrote.

“Medication-Related Osteonecrosis of the Jaw – 2022 Update” was developed by three authors of the 2014 AAOMS position paper on MRONJ, along with three member of the Association’s Committee on Oral, Head, and Neck Oncologic and Reconstructive Surgery. In addition to Drs. Ruggiero and Dodson, authors include Tara Aghaloo, DDS, MD, PhD, UCLA School of Dentistry; Eric R. Carlson, DMD, MD, EdM, University of Tennessee Graduate School of Medicine; Deepak Kademani, DMD, MD, North Memorial Health and the University of Minnesota; and Brent B. Ward, DDS, MD, University of Michigan Hospital.

At an MRONJ presentation during AAOMS’s 104th Annual Meeting, Scientific Sessions and Exhibition in New Orleans in September, Carlson told attendees the update was needed to reflect numerous advancements in MRONJ knowledge over the past eight years.

“It became very clear to our national organization that there were many substantial and very interesting changes in terms of our understanding of this disease, particularly with regard to its treatment,” he said.

Carlson said the updated definition of an MRONJ case includes three elements:

  • Current or previous treatment with antiresorptive therapy alone or in combination with immune modulators or antiangiogenic medications.
  • Exposed bone or bone that can be probed in the maxillofacial region that has persisted for more than eight weeks.
  • No history of radiation therapy to the jaws or obvious metastatic disease to the jaws.

“MRONJ is preventable, resectable and reconstructable in a very predictable fashion,” said Carlson. “The new position paper will help medical and dental professionals in their treatment of patients who require these medications.”

Read the full position paper at AAOMS.org/MRONJ.

Innovation Fertility, Led by Fertility Care Experts, Announces Launch Ahead of ASRM


Follow the science, transform the care. Innovation Fertility, a network of leading IVF clinics and laboratories, has announced its formal launch ahead of the American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo. in Anaheim, CA, October 22-26, 2022. This is the premier event for reproductive medicine, drawing top experts from around the world.

Innovation Fertility is led by a dynamic and seasoned team of reproductive health and business professionals with years of experience in building successful fertility practices. Their decades of expertise spans laboratory design, technology implementation, strategic planning, and operations support.

“We have been working toward this pivotal moment for some time,” says Dwight P. Ryan, CEO of Innovation Fertility. “Our mission is to leverage our collective experience to empower our partner practices and help deliver better outcomes for more families. But we want these practices to retain what makes them unique and trusted by their patient population.”    

The forward-thinking theme of the ASRM 2022 meeting — “Genes, Gametes, and Genetics: What Will the Future Hold?” — is in-step with the organization’s new core messaging, which asks practices to imagine “What IF?” Innovation Fertility is on the other side of that question, offering greater efficacy, more support, and better technology. In a time when much value is often placed on the disruptive era of fertility care, Innovation places greater emphasis on following the science and embracing innovative, evidence-based solutions.

“For years, the leadership team has brought the best technology and laboratory practices to fertility clinics,” says Dr. Kathleen Miller, Chief Science Officer at Innovation Fertility. “We are known for being data-driven, science-first insiders. It’s exciting to have a brand that elevates our work and commitment to our practice partners, but we’re also proud to be more than a brand. Years of research, dedication, and big thinking have gotten us here.”

Though ASRM will mark the organization’s formal debut, Innovation Fertility has already been working with fertility practices across the country, giving them the autonomy to run day-to-day operations as they see fit, while bolstering them with the additional support they need to streamline internal operations and scale accordingly.

Learn more about Innovation Fertility at ASRM, October 22-26, 2022 at booth 1502.

ABOUT INNOVATION FERTILITY

Innovation Fertility provides patients with innovative, cutting-edge fertility treatment options to meet their unique family planning goals. As a team, they combine premier reproductive endocrinologists with laboratory operations, resulting in exceptional medical care and an unparalleled patient experience.

Share article on social media or email:

EK Health Introduces Billtelligent™ to Transform Medical Bill Review Technology


(Photo: EK Health)

We did not want to create another software for software’s sake. With Billtelligent™, we have control at all levels and can bring the change our industry deserves. We will be faster, flexible and more accurate. Eunhee Kim, EK Health’s Owner & CEO

EK Health Services Inc. proudly announces the launch of Billtelligent™, a proprietary technology that is taking medical bill review in workers’ compensation to the next level. Billtelligent™ eliminates barriers for EK Health, empowering an independence the national managed care company had not previously realized.

Billtelligent™ leverages a unique cloud-based, modular design focused on efficient bill handling through innovative strategies, supported by nimble technology. Billtelligent™ promotes flexibility through intelligent routing, automation, auto-adjudication and the ability to customize workflows with incredible specificity (without cumbersome management requirements). “We did not want to create another software for software’s sake,” said Eunhee Kim, EK Health’s Owner & CEO. “With Billtelligent™, we have control at all levels and we can bring the change our industry deserves. We will be faster, flexible and more accurate. This gives us the ability to better optimize managed care strategies and improve quality of care for injured workers – which is our ultimate focus.”

EK Health Services Inc. is keeping with its promise to transform the workers’ compensation industry as an innovator dedicated to integrity, transparency, and customer-focused solutions. “We have been asked many times to ‘demystify medical bill review’, due to the unnecessary complexities, exorbitant fees and undisclosed revenue sharing that exists today,” shared Zebrah L. Jahnke, VP of Business Development. “We knew offering transparency required full ownership of our processes and technology. The first step to breaking barriers is identifying them and then having the ability to actively affect change. Billtelligent™ does that – it allows us to dream and implement the absolute best processes that generate the greatest outcomes. Billtelligent™ is intelligent bill review.”

Developing Billtelligent™ speaks directly to EK Health’s belief that the work comp industry can be cutting edge, consistently offering fresh ideas. EK Health recognizes that providers should be paid faster, burdens should be reduced for claims adjusters, and intelligent workflows can promote reliable results. With advances in automation, and the implementation of their new technology, EK Health has written an exciting new chapter for the future of bill review through Billtelligent™.

“It was clear to me that we needed to be free from the constraints of leased software to fully realize our potential. With Billtelligent™ , we have direct access to PPOs, allowing us to create our own onboarding and custom network design,” Kerri Wilson, EK Health’s President & Chief Operating Officer explained. “Billtelligent™ is the start of a new journey towards client-choice and decision-making in bill review. This freedom results in increased bottom-line savings and provider/client satisfaction at all levels. We are embracing independence that empowers us to serve our customers nimbly without bias, and placing solutions before profits.”

Benefits/Advantages

Billtelligent™ – a bill review technology built today, designed for tomorrow:

  • Stands alone in design, functionality, and customization
  • Was built from the ground up by EK Health, giving complete independence and ownership
  • Is a modern bill review technology designed to evolve
  • Removes barriers through automation & limitless creative workflows
  • Replaces complexity with simplicity
  • Supports EK Health client programs with reduced turnaround times
  • Ensures quality results through efficient execution


Key Features & Differentiators

  • Intelligent trigger-based routing for near real-time bill processing as the rule, batch processing as the exception
  • Real-time access; real-time status; real-time fixes – all before a bill is finalized
  • Sophisticated pended-bills load balancing to optimize workforce productivity
  • User-friendly, customizable client portal allows external users access to view bills for approval/denials within the bill’s life-cycle
  • Highly configurable and flexible system requiring minimal code changes to introduce new features, adapt to future requirements and onboard new clients
  • Limitless unique bill routing workflows, automate agreements, and manage client-specific network structures

A process long driven by antiquated, cumbersome, and inflexible solutions is being revolutionized with EK Health’s Billtelligent™. Through this innovative technology, EK Health is not just meeting clients where they are today, EK Health is taking them into the future with nimble solutions realizing immediate gains. For details on this enhanced bill review technology, visit ekhealth.com/Billtelligent.

About EK Health

EK Health Services Inc. is a leading national workers’ compensation managed care organization. EK Health restores quality of life for injured workers through innovative, cost-effective solutions, while providing client services with high-touch experiences, customizable solutions, lower costs, and proven results. Their holistic approach integrates the best people, processes, and technology to facilitate the best medical treatment available for return-to-work possibilities. For more information, visit ekhealth.com.

Share article on social media or email:

FSHD Society establishes genetic testing program to advance clinical trial readiness for facioscapulohumeral muscular dystrophy


TestFSHD logo

“I came back with a positive blood test [for] FSHD Type 1. I am ready and willing to take part in any clinical trials as soon as I’m able.” – Patient 1

The FSHD Society has launched a direct-to-patient clinical diagnostic genetic testing program for facioscapulohumeral muscular dystrophy (FSHD). Called TestFSHD, the program’s aim is to overcome critical barriers that patients currently face when trying to obtain genetic testing for the rare, debilitating muscle disorder. FSHD is one of the most common hereditary muscle diseases and is thought to affect nearly one million individuals world-wide. Because of widespread lack of access to diagnostic testing, the majority of those who have FSHD have not had their diagnosis confirmed genetically.

The TestFSHD program ensures that eligible U.S.-based patients seeking a clinically approved genetic diagnosis of FSHD have a comprehensive and streamlined path to a genetic test. The program provides virtual genetic counseling, medical referrals, mobile blood-draws, and comprehensive FSHD1 and FSHD2 genetic testing. These services are provided by Genome Medical, a telemedicine company specializing in genetic counseling, with blood-draws by ExamOne phlebotomy service and genetic tests requisitioned from commercial diagnostic laboratories such as PerkinElmer Genomics and the University of Iowa Diagnostic Laboratories. Genome Medical counselors can also assist patients in filing claims with their health insurance.

“Confirmation of FSHD by a clinically approved genetic test remains one of the primary barriers impacting rapid recruitment into clinical trials,” explains Jamshid Arjomand, PhD, Chief Science Officer at the FSHD Society. “The TestFSHD program provides patients with a solution to overcome barriers to clinical trial eligibility, which should help streamline the recruitment process in upcoming trials.”

The lack of access to genetic testing had become an obstacle to progress because many treatments being developed for FSHD target the genetic cause of the condition. This means that patients must be genetically confirmed to have FSHD before they can enroll in clinical trials or, eventually, be eligible to receive such treatments. The Society noted that the low percentage of patients with genetically confirmed FSHD could undermine or slow down upcoming clinical trials. To build up a ‘trial-ready’ patient population, the FSHD Society analyzed the obstacles faced by patients, identified the partner companies to provide solutions, and established a process so each part of the system connected smoothly to the others.

The program has clearly had its intended impact. “I was diagnosed with FSHD over 11 years ago,” said one individual. “I recently completed the free genetic testing that you offered, and I met with the genetic counselor yesterday…I came back with a positive blood test [for] FSHD Type 1. I am ready and willing to take part in any clinical trials as soon as I’m able.”

The FSHD Society partnered with Arrowhead Pharmaceuticals, Avidity Biosciences, Dyne Therapeutics, Fulcrum Therapeutics and Pfizer to sponsor a pilot of TestFSHD, which made the testing free for the first 150 qualifying patients. “These partnerships demonstrate the enthusiasm of key stakeholders to collectively advance a trial-ready patient community in collaboration with the FSHD Society,” remarks Ken Khatava, Chief Growth Officer at the FSHD Society.

The sponsored, free phase of the program will end on October 31, 2022, but TestFSHD will remain in place to make it easy for patients and families to obtain clinical genetic testing, with the cost reimbursed by their health insurance or covered out of pocket. “The extreme difficulty of getting genetic testing for FSHD has long been a pain point in the patient journey,” explains Arjomand. “We are thrilled that TestFSHD empowers patients to obtain affordable genetic testing for themselves.”

To learn more, visit fshdsociety.org/testfshd

ABOUT THE FSHD SOCIETY

The FSHD Society is the world’s largest research-focused patient advocacy organization for facioscapulohumeral muscular dystrophy (FSHD), one of the most prevalent forms of muscular dystrophy. The Society has catalyzed major advancements and is accelerating the development of treatments and a cure to end the pain, disability, and suffering endured by one million people worldwide who live with FSHD. The FSHD Society has transformed the landscape for FSHD research and is committed to making sure that no one faces this disease alone. The Society offers a community of support, news, and information through its website at fshdsociety.org

Share article on social media or email: